Randox at MEDLAB Middle East 2019 - Stand No. Z5.B10

Location : World Trade Centre Dubai
  Date : 4th - 7th of February 2019

New Products

Qnostics Molecular Controls

Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing, supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, Pharmaceutical and CRO organisations for over a decade.

Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.

Qnostics Molecular Controls

The Qnostics range of complete molecular infectious disease control solutions can be used in the daily monitoring of assay performance, linearity assessment, assay evaluation, validation/verification of new assays and staff training. As whole pathogen controls, the range is designed to mimic the performance of patient samples and can be used to effectively monitor the entire testing process including extraction, amplification and detection.

  • Q Controls – Independently manufactured, this range of positive run, whole pathogen, third party controls are designed to monitor the daily performance of a wide range molecular assays used in the detection of infectious diseases. These controls help in supporting a laboratory’s accreditation requirements in line with ISO 15189:2012.
  • Analytical Q Panels – Designed to cover the dynamic range of an assay, Analytical Q Panels allow assessment of an assays linearity, LOD and LOQ. Each panel contains a minimum of five samples, including a negative, that span the dynamic range of the assay in a linear progression.
  • Molecular Q Panels – Consisting of three levels (high, medium and low), Molecular Q Panels are intended to evaluate an assays analytical measuring range.  Molecular Q Panels can also be used to support training of laboratory staff and in the development of molecular diagnostic assays.
  • Evaluation Panels – Evaluation Panels cover a range of genotypes and may be used to evaluate assay characteristics, confirm performance claims and ultimately ensure the assay is fit for purpose. Evaluation Panels may also be used in the validation of molecular assays and development of new molecular diagnostic assays.
  • QCMD Past Panels – Available for use in assay evaluation and staff training, EQA samples are available from past QCMD challenges.
  • Custom Manufacture – Qnostics are specialists in the custom manufacture of quality control materials for use in the detection of infectious diseases using molecular based methods. Qnostics will work with you to develop a bespoke solution designed specifically to meet the individual and unique requirements of your lab.

QCMD

QCMD is a world leading External Quality Assessment (EQA) / Proficiency Testing (PT) scheme, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases.

With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of molecular diagnostics.

  • Frequency – A variety of programme options are available.  Choose the number of challenges that best suit your laboratory’s  requirements.
  • Online EQA Management System – ITEMS provides an online tool to easily manage all EQA activities from programme registration to submission of results and provision of EQA reports. Different levels of user access are available so data can be accessed by whoever needs it.
  • High level of participation – Over 2000 participants in more than 100 countries ensuring peer group numbers are maximised.
  • Comprehensive reports – Receive individual reports for each challenge and a final supplementary report at the end of the cycle visual assessment of performance.
  • International accreditation – Programmes are accredited to ISO 17043. 

The Evidence MultiSTAT is an automated analyser that enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs from a single sample. Designed to work across a variety of matrices, our patented multi-analyte testing platform provides a complete immunoassay profile within minutes, changing the landscape of drug detection forever.

As Minimal sample preparation is required, qualitative results can be provided in under 20 minutes, offering an efficient and accurate toxicology screen. Available matrices include oral fluid, with blood and urine coming soon.

Whole Blood Panel

α-PVP (Flakka)
AB-PINACA
Amphetamine
Barbiturates
Benzodiazepines
BZG/Cocaine
Buprenorphine
Cannabinoids (THC)
Carfentanil
EtG
Fentanyl
Methadone
Methamphetamine
Opiate
Oxycodone
Phencyclidine (PCP)
Synthetic Cannabinoids (UR-144/XLR-11)
Tramadol
Tricyclic Antidepressants (TCA)
JWH-018
6-MAM

Urine I Panel

α-PVP (Flakka)
AB-PINACA
Amphetamine
Barbiturates
Benzodiazepines I (Oxazepam)
Benzodiazepines II (Lorazepam)
Benzoylecgonine (Cocaine Metabolite)
Buprenorphine
Cannabinoids (THC)
Creatinine
EtG
Fentanyl
Methadone
Methamphetamine
Opiates
Oxycodone
Tramadol
Tricyclic Antidepressants (TCA)
UR144 / XLR11
JWH-018
6-MAM

Urine II panel

α-PVP
AB-CHMINACA
AB-PINACA
Amphetamine
Barbiturates
Benzodiazepine
BZG (Cocaine Metabolite)
Creatinine
EtG (Ethyl Glucuronide)
Fentanyl
Methadone
Methamphetamine
Opiates
PCP (Phencyclidine)
Pregabalin
TCA (Tricyclic Anti-depressants)
THC (Cannabinoids)
Tramadol
UR-144 (Synthetic Cannabinoids)
6-MAM

Oral Fluid Panel

α-PVP (Flakka)
Amphetamine
Barbiturates
Benzodiazepines I (Oxazepam)
Benzodiazepines II (Lorazepam)
Benzoylecgonine (Cocaine Metabolite)
Buprenorphine
Cannabinoids (THC)
Fentanyl
Ketamine
LSD
Methadone
Methamphetamine
Opiates
Oxycodone
Phencyclidine (PCP)
Tramadol
UR144 / XLR11
JWH-018
6-MAM

Vivalytic

Vivalytic enables sample-to-answer, cartridge based molecular diagnostics powered by Randox patented Biochip Array Technology (BAT). PCR, extraction and detection are combinable in a fully automated manner with minimal sample preparation required. Manual test preparation, cold chain reagents or the use of different devices are no longer required.

No further peripherals such as a laptop, keyboard, barcode or scanner or filling station are required making the Vivalytic a spacing saving hygienic solution for your molecular diagnostics.  The sample to result process is quicker than ever with results from 30 minutes, depending upon test complexity allowing healthcare professionals additional time to complete other important tasks.

Infectious Disease

  • Respiratory Tract Infection Array
  • Sexually Transmitted Infection Array

Inherited Diseases

  • Familial Hypercholesterolemia (FH) Arrays I & II

Mutation Analysis

  • KRAS, BRAF & PIK3CA* Array

SNP Genotyping

  • Cardiac Risk Prediction Array

sdLDL-C

A niche product from Randox, sdLDL-C, a subtype of LDL cholesterol, can more readily permeate the inner arterial wall. Research indicates that individuals with a predominance of sdLDL-C have a 3-fold increased risk of myocardial infarction.

When measuring LDL cholesterol (LDL-C), it is the cholesterol mass within the LDL particles that is being measured. The LDL particle population within LDL is heterogeneous – meaning that the size, density & composition of each particle will be different. sdLDL-C is a subfraction of low density lipoprotein (LDL) with smaller particle size and higher density than larger more buoyant LDL. They all transport triglycerides and cholesterol to the tissues, but their atherogenesis varies according to their size. sdLDL-C will more readily permeate the inner arterial wall. sdLDL-C is more susceptible to oxidation and has a lower affinity to the hepatic LDL receptor, and as such circulates in the blood longer.

The only direct automated sdLDL-C kit on the market, the Randox sdLDL-C ‘Ex-Seiken’ test is a direct method for the quantitative determination of sdLDL-C using automated chemistry analysers capable of accommodating two-reagent assays. The assay consists of two steps and is based on the use of well-characterised surfactants and enzymes that selectively react with certain groups of lipoproteins.

Find out more about sdLDL-C

sTfR

Soluble transferrin receptor (sTfR) is a new diagnostic assay, expanding the current iron deficiency testing panel. sTfR, a truncated form of the transferrin receptor (TfR), is a valuable diagnostic tool for the differential diagnosis of anaemia: iron deficiency anaemia (IDA) and anaemia of chronic disease (ACD).

In IDA, increased sTfR levels have been observed in haemolytic anaemia, sickle cell anaemia, B12 deficiency and functional iron deficiency in pregnancy.

In ACD, sTfR levels do not correlate with iron status. This was observed in patients with chronic illnesses (cystic fibrosis and cancer), certain infections, autoimmune diseases (insulin-dependent diabetics) and inflammatory diseases.

The Randox sTfR assay offers the following key benefits:

  • Liquid ready-to-use reagent
  • Latex Enhanced Immunoturbidimetric method
  • Excellent measuring range
  • Excellent correlation
  • Applications for a wide range of biochemistry analysers

Find out more about sTfR

Direct HbA1c

The Randox RX series welcomes the addition of Direct HbA1c testing on the RX Daytona +, RX imola and RX modena. The latex enhanced immunoturbidimetric method which the RX series utilises makes the test simple and quick to perform. The removal of the pre-dilution step removes the risk of human error compromising your results.

Testing for HbA1c gives us an indication of what an individual’s average blood sugar level has been over recent weeks/months. This is significant for those who suffer from diabetes because the higher the levels of HbA1c the higher the chance of an individual suffering from further diabetes related issues. With a wide range of benefits, the RX series Direct HbA1c testing capabilities can revolutionise your testing capabilities

Accurate QC Recovery & Sample Recovery

Inaccuracies in sample and QC recovery are reduced as the offline preparation stage is now eliminated. By reducing the chance of results being compromised by human error the RX series direct HbA1c test creates a more effective laboratory and improves accuracy of diagnosis.

Fast Recovery Times

No offline calculations ensures faster recovery times. The RX series direct HbA1c test will increase your laboratories efficiency and will increase testing throughput.

Quick Calibration & QC Generation

Single assay testing allows faster QC and calibration. This is another time saving benefit of the RX series direct HbA1c which will further improve your laboratories efficiency.

No Incubation Step

No incubation step allows samples to be run immediately, the removal of the human interaction stage which is necessary on the traditional HbA1c methodology will ensure a higher level of accuracy and patient confidence in the results produced.

Liquid Lipid Control

Cardiovascular disease (CVD) is a general term for conditions affecting the heart or blood vessels. It is usually associated with a build-up of fatty deposits inside the arteries and increased risk of blood clots. It can be associated with damage to arteries in organs such as the brain, heart, kidney and eyes. Some types of CVD include coronary heart disease, strokes and aortic disease. Some of the main causes of CVD are smoking, high cholesterol, diabetes and high blood pressure (NHS, 2016).

These diseases can be extremely dangerous and lead to permanent damage or even death, therefore, it is vitally important for laboratories to be confident in their analyser’s ability to accurately diagnose and monitor the risk of these diseases.

The Randox Acusera Liquid Lipid quality control includes assayed target values and ranges for 8 analytes covering the complete lipid profile. With a 30 day open vial stability the Acusera Liquid Lipid control will reduce waste, whilst remaining easy and convenient to use. Containing no Sodium Azide, which can interfere with direct clearance methods for  detecting HDL and LDL cholesterol, ensuring ultimate accuracy and confidence in results.

  • Liquid ready-to-use – offering optimum convenience and ease of use
  • 100% human serum
  • Assayed target values provided
  • True third party control
  • Stable to expiry date at -20°C to -80°
  • Open vial stability of 30 days at 2°C to 8°C

The Evidence Evolution sets new standards in diagnostic testing, bringing unrivalled versatility, quality and efficiency to deliver precise results quickly and economically. Widely used across the world for ten years, multiplex testing with our patented Biochip Array Technology has a proven record of quality results and provides complete patient profiling.

Offering batch analysis, STAT samples, true random access and the capability of running 2640 tests per hour, the Evidence Evolution is a highly versatile analyser which can process any required workflow. View our test menu below.

Any Test,
Any time

Evidence Evolution is a highly versatile analyser which can process any required workflow including batch analysis, STAT samples and true random access. The test menu includes stroke, Alzheimer’s risk, thyroid and toxicology arrays.

Workflow Optimisation

With continuous sample and reagent loading, alongside automated on-board sample dilution and sample information entry; the Evidence Evolution with a walk away time of 2 hours is a convenient solution for busy laboratories.

Cost Consolidation

Multiplex technology allows numerous tests to be performed from a single patient sample, reducing the amount of time and labour spent on individual tests, while also providing a complete patient profile.

Enhanced User Experience

Highly intuitive software, customisable user settings and easy to follow result screens ensures usability, allowing laboratories to achieve fast and accurate operations with uncompromised quality.